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Aberrant activation of Hedgehog (HH)/GLI signaling is causally involved in numerous human malignancies, including basal
cell carcinoma (BCC) and medulloblastoma. HH pathway antagonists targeting smoothened (SMO), an essential effector of
canonical HH/GLI signaling, show significant clinical success in BCC patients and have recently been approved for the treat-
ment of advanced and metastatic BCC. However, rapid and frequent development of drug resistance to SMO inhibitors
(SMOi) together with severe side effects caused by prolonged SMOi treatment call for alternative treatment strategies tar-
geting HH/GLI signaling downstream of SMO. In this study, we report that 4SC-202, a novel clinically validated inhibitor of
class I histone deacetylases (HDACs), efficiently blocks HH/GLI signaling. Notably, 4SC-202 treatment abrogates GLI activa-
tion and HH target gene expression in both SMOi-sensitive and -resistant cells. Mechanistically, we propose that the inhibi-
tion of HDACs 1/2/3 is crucial for targeting oncogenic HH/GLI signaling, and that class I HDAC inhibitors either in
combination with SMOi or as second-line therapy may improve the treatment options for HH-associated malignancies with
SMOi resistance.
Hedgehog (HH)/GLI signaling plays a pivotal role in many
human malignancies. Notably, targeted pathway inhibition has
shown clinical success particularly in HH-driven basal cell carci-
noma (BCC) and medulloblastoma.1,2 However, rapid and fre-
quent development of resistance to HH inhibitors urgently calls
for additional treatment options.3 Canonical HH/GLI signaling is
initiated by the binding of secreted HH protein to Patched
(PTCH), a transmembrane domain protein that represses HH
signaling in its unliganded state by inhibiting the ciliary localiza-
tion and activation of the essential HH effector Smoothened
(SMO). Binding of HH to PTCH allows the translocation of SMO
into the primary cilium, where activated SMO triggers the forma-
tion of active GLI transcription factors (GLI2 and GLI3) by pre-
venting proteolytic GLI repressor formation and by releasing
them from their repressor Suppressor of Fused (SUFU) (for
reviews, see Refs.4,5). Active full-length GLI proteins translocate
to the nucleus, where they induce HH target gene expression
including the strong transcriptional activator GLI1 that not only
amplifies HH signal strength but whose expression level also
serves as robust readout for HH/GLI pathway activation.6
Active GLI proteins drive tumor formation and promote
cancer progression by inducing proliferation, survival, self-
renewal and metastasis.7,8 To target oncogenic HH/GLI
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signaling, small molecule SMO inhibitors (SMOi) have been
developed. Vismodegib and sonidegib represent two FDA-
approved SMOi for the treatment of advanced and metastatic
BCC, a nonmelanoma skin cancer driven by aberrant activation
of HH/GLI signaling.1,9 Despite striking therapeutic efficacy,
severe side effects of SMOi drugs and frequent development of
SMOi resistance pose major challenges to future HH pathway
inhibitor therapies.3,10,11 Therefore, the identification of targets
and drugs to be used in combination or as an alternative to
SMOi, particularly in settings of SMOi-resistance, is critical to
improve anti-HH-therapies in oncology.
Targeting epigenetic regulators such as histone deacetylases
(HDACs) has proven a successful therapeutic option in several
malignancies. Intriguingly, HDACs have been shown to modu-
late the activity of HH/GLI signaling with evidence for both a
positive and repressive impact, demanding selective inhibition
of HDACs, which enhance oncogenic HH/GLI signaling.12–15
In this study, we show that the clinically suitable class I
HDAC inhibitor (HDACi) 4SC-202 efficiently abrogates
HH/GLI signaling in a human model of oncogenic HH/GLI
signaling. Importantly, 4SC-202 inhibited HH/GLI signaling
in both, SMOi-sensitive and SMOi-resistant settings and
interfered with the growth of HH/GLI-dependent BCC cells
in vivo, thereby identifying 4SC-202 as a promising epigenetic
drug for the treatment of HH-driven cancers.
Materials and Methods
For an extended version of Materials and Methods, see
Supporting Information.
Cell culture and in vivo assays
NIH/3T3 Gli reporter cells (AMS Biotechnology) were used
to monitor Hh pathway activity in response to chemical
treatments and cell viability was assayed in parallel.
To study human HH/GLI signaling, we applied Daoy medul-
loblastoma cells (ATCC HTB-186) responsive to chemical and
genetic pathway activation. The following chemicals were used:
Smoothened agonist SAG (Axxora), vismodegib and entinostat
(LC Laboratories), OG-L002, SAHA/vorinostat and 4SC-202
(4SC AG). Cell proliferation and viability were determined by
Alamar Blue assays (see extended materials and methods).
In vivo experiments were done in NSG mice. Following ran-
domization of mice with palpable tumors, mice were treated
with 4SC-202 (80 mg/kg/day per oral gavage) or solvent.
Tumor volume was measured every 2–3 days using a caliper.
RNA isolation and quantitative PCR (qPCR)
Total RNA was isolated using TRI reagent (Sigma-Aldrich)
according to manufacturer’s protocol followed by LiCl
precipitation. qPCR was done on a Rotor-Gene Q (Qiagen)
using GoTaq 23 qPCR Mastermix (Promega). qPCR primers
are listed in Supporting Information, Table 1.
Western blot analysis, chromatin immunoprecipitation
(ChIP) and immunohistochemistry
For protein detection by Western blot analysis, the following pri-
mary antibodies were applied: anti-GLI1 (V812), anti-Beta Actin
(D6A8), anti-HDAC1 (D5C6U), anti-HDAC2 (D6S5P), anti-
HDAC3 (7G6C5), anti-p44/42 MAPK (Erk1/2), anti-PCNA
(D3H8P), anti-Cyclin D1 (92G2), anti-b-Tubulin (9F3, all Cell
Signaling) and anti-SUFU (sc-10933, Santa Cruz Biotechnology).
ChIP assays were conducted using the SimpleChIP Kit (Cell
Signaling) with cross-linked chromatin immunoprecipitated over-
night with either anti-H3K27ac antibody (D5E4) or anti-MYC-
tag antibody (9B11) or mouse IgG isotype control (Cell Signaling).
Immunohistochemistry was done on FFPE tissue of three different
skin specimens with diagnosis of BCC. Sections were stained using
the following primary antibodies: anti-HDAC1 (ab19845, Abcam
1:2000,), anti-HDAC2 (ab16032, Abcam, 1:250) and anti-HDAC3
(sc-11417, Santa Cruz Biotechnology), 1:100).
RNA interference
SUFU knockdown was done by lentiviral shRNA transduction
as described in Ref. 16. The SUFU targeting shRNA construct
was selected from the Mission TRC shRNA library
(TRCN0000019466, Sigma) and a scrambled shRNA served as
control (SHC002, Sigma). HDAC1, HDAC2 or HDAC3 and
LSD1 expression was knocked down using the following
ON-TARGET plus siRNAs (siHDAC1 (L-003493–00); siH-
DAC2 (L-003495–02); siHDAC3 (L-003496–00) and siLSD1
(KDMA1) (L-009223–00–0005), Dharmacon), according to
manufacturer’s instructions. The ON-TARGET plus nontarget-
ing siRNA served as control (D-001810–01–05, Dharmacon).
Results
4SC-202 inhibits canonical HH/GLI signaling in
murine and human HH-responsive cells
4SC-202 is a novel small-molecule inhibitor selectively target-
ing class I HDACs 1/2/3 and the lysine-specific demethylase
LSD1.17 Notably, 4SC-202 has shown excellent safety and
promising anti-leukemic activity in a recent phase I clinical trial
What’s new?
Inhibition of signaling by Hedgehog polypeptide and the effector protein GLI is an effective therapeutic strategy for basal cell
carcinoma and medulloblastoma. The frequent development of resistance to Hedgehog pathway inhibitors (HPI), however, calls
for the identification of alternative drugs. This study identifies the class I histone deacetylase inhibitor 4SC-202 as a novel
Hedgehog/GLI antagonist. A clinically suitable small molecule, 4SC-202, showed inhibitory efficacy, blocking GLI activation
and Hedgehog target gene expression, even in cells with acquired HPI resistance. The findings suggest that 4SC-202 could be
effective against Hedgehog-driven cancers that are refractory to standard targeted therapy.
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(see TOPAS study at clinicaltrials.gov trial no. NCT01344707
and J Clin Oncol 32:5 sec, 2014 (suppl; abstr 8559)). To analyze
whether 4SC-202 affects HH/GLI signaling, we first treated
Sonic Hh stimulated murine Hh/Gli luciferase reporter cells
with 4SC-202 and found that 4SC-202 strongly repressed Gli
activity with an IC50 of 50 nM (Fig. 1a). To address the
relevance of this finding to physiological HH/GLI signaling in a
human context, we used HH responsive human medulloblas-
toma cells (i.e., Daoy) as a human model of canonical HH/GLI
signaling in cancer cells.18 Daoy cells and NIH/3T3 express
robust levels of HDAC1/2/3 (Figs. 1b and 1c) and activation of
HH signaling by Smoothened agonist SAG induces HH target
genes (e.g. GLI1 and HHIP) at the mRNA and protein level.18
Notably, 4SC-202 treatment efficiently repressed SAG-induced
GLI1 (Fig. 1d) and HHIP (Fig. 1e) expression with an IC50 of
240 nM and 140 nM, respectively, without affecting pri-
mary cilia formation, an essential process for the coordination
of HH/GLI signal activation (Supporting Information, Fig. 1).19
Analysis of GLI1 protein expression confirmed the
concentration-dependent repressive effect of 4SC-202 on HH/
GLI signaling (Figs. 1f and 1g). RNAi-mediated inhibition of
individual class I HDACs in Daoy cells suggests a dominant
role for HDAC3, though the repressive effect on HH target
gene activation was less pronounced when compared to 4SC-
202 treatment, most likely due to functional redundancy of
class I HDACs (Supporting Information, Fig. 2). Furthermore,
and in line with the proliferative role of HH/GLI in medullo-
blastoma, 4SC-202 treatment also reduced the growth of SAG-
stimulated Daoy cells (Fig. 1h).
4SC-202 inhibits HH/GLI signaling by targeting
class I HDACs
4SC-202 displays a unique inhibitor profile blocking not only
the class I HDACs HDAC1/2/3, but also the lysine-specific
demethylase LSD1 (Fig. 2a), which has been shown to play
key roles in many malignancies. To investigate whether
4SC-202 represses HH/GLI by inhibiting LSD1, we first
tested the potent LSD1 inhibitor OG-L00220 on SAG-
stimulated Daoy cells. As shown in Figure 2b, OG-L002 only
moderately repressed SAG-induced HH signaling to 75% of
controls as monitored by GLI1 mRNA expression analysis. Fur-
thermore, siRNA-mediated knockdown of LSD1 (Supporting
Information, Fig. 3) did not reduce GLI1 mRNA levels in
response to SAG stimulation (Fig. 2c). Thus, we conclude that
the repressive effect of 4SC-202 on HH/GLI signaling does not
involve inhibition of LSD1. To further support the requirement
of class I HDACs in HH/GLI signaling, we treated SAG-
stimulated Daoy cells with the selective HDAC1/2/3 inhibitor
entinostat.21 Similar to 4SC-202, entinostat effectively reduced
GLI1 and HHIP expression in a concentration-dependent man-
ner (Figs. 2d and 2e). By contrast, treatment with the FDA-
approved pan-HDAC inhibitor SAHA (vorinostat) was unable
to efficiently abrogate HH/GLI signaling (Fig. 2f), which may
be a consequence of targeting HDAC6, whose inhibition has
been shown to promote ciliogenesis and HH signaling.14
Together, we conclude that 4SC-202 represses HH/GLI signal-
ing by blocking class I HDACs, in line with a recent report
identifying HDAC1/2 as important positive effectors of HH/
GLI signaling in a murine model of medulloblastoma.15
4SC-202 represses HH/GLI signaling in
SMO-inhibitor-resistant human cancer cells
HH/GLI pathway inhibitors targeting SMO (SMOi) have
been approved for the treatment of advanced and metastatic
BCC.22 However, frequent development of resistance to
SMOi urgently calls for further drug targets and drugs block-
ing HH/GLI signaling downstream and independent of SMO
activity and resistance status.11 HDACs have previously been
shown to activate GLI proteins by modifying their acetylation
status.12,15 We thus hypothesized that 4SC-202 interferes
with oncogenic HH/GLI signaling downstream of SMO at
the level of the GLI transcription factors that would allow
HH/GLI targeting even in SMOi resistant cells. To this end,
we first generated SMOi-resistant Daoy cells by genetically
depleting the endogenous GLI inhibitor SUFU. As shown in
Figures 3a and 3b, SUFU-depleted Daoy cells express high
levels of GLI1 protein and mRNA independent of SAG or
SHH stimulation. SUFU-deficient Daoy cells were resistant to
the FDA-approved SMOi vismodegib, as evidenced by the
inability of vismodegib to reduce the direct HH targets GLI1
and HHIP (Figs. 3c and 3d). Notably and in contrast to vis-
modegib, 4SC-202 treatment reduced the expression of GLI1
and HHIP also in SMOi-resistant Daoy cells at IC50 concen-
trations similar to those determined in the SMO-dependent
wild-type Daoy model (Figs. 3c and 3d, compared to Figs. 1d
and 1e). We confirmed these observations also at the protein
level by showing that 4SC-202, but not vismodegib, was able
to reduce GLI1 protein expression in SUFU-deficient Daoy
cells (Figs. 3e and 3f). Consistently, 4SC-202 also repressed
the growth of both SMOi sensitive (wild-type) and SMOi-
resistant (shSUFU) Daoy cells in a concentration-dependent
manner (Supporting Information, Fig. 4).
Acetylation of GLI1 has been suggested to decrease its DNA
binding capacity.12 We therefore applied chromatin immuno-
precipitation (ChIP) of GLI1 to test whether HDAC1/2/3
inhibition by 4SC-202 is able to reduce GLI1 binding to the
promoter of the GLI1 target PTCH. We found that 4SC-202
treatment markedly reduced binding of GLI1 to the PTCH
target promoter (Fig. 3g), despite enhancing transcriptional
activation marks (i.e., histone 3-K27 acetylation) (Supporting
Information, Fig. 5). These data corroborate the findings by
Canettieri et al. (2010)12 and are in line with the hypothesis
that HDAC inhibition by 4SC-202 decreases the DNA-binding
capacity of GLI1 by increasing its acetylation, although we
failed to reliably detect changes in endogenous GLI acetylation
due to the low GLI expression levels in Daoy cells.
To analyze a possible effect of 4SC-202 treatment on GLI
processing, we used Ptch1 deficient Med1 cells derived from a
genetic mouse model of medulloblastoma. Notably, treatment
of Med1 cells with 4SC-202 not only reduced Gli1 expression,
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Figure 1. Inhibition of HH/GLI signaling by 4SC-202. (a) Quantification of Hh/Gli signal strength in response to 4SC-202 treatment using NIH/
3T3 Hh reporter cells containing an 8x-Gli binding site driving luciferase expression in response to Hh pathway activation. Hh/Gli luciferase
reporter cells were stimulated with 1 lg/ml of recombinant Shh and treated with the respective 4SC-202 concentrations. Luciferase activity and
cell viability were measured after 24 hr of treatment. RLU: relative light units. (b and c) qPCR and Western blot analysis of HDAC1/2/3 mRNA lev-
els in Daoy (b) and protein expression in HH-responsive Daoy and NIH/3T3 cells (c). (d and e) qPCR analysis of GLI1 (d) and HHIP (e) mRNA
expression in SAG-stimulated Daoy cells exposed to increasing concentrations of 4SC-202. GLI1 and HHIP mRNA levels in SAG-treated Daoy cells
without 4SC-202 were set to 100%. (f) Western blot analysis of Daoy cells treated with respective concentrations of vismodegib or 4SC-202.
(g) Relative densitometric quantification of protein levels shown in (f). (h) Proliferation analysis of SAG-stimulated Daoy cells in response to
4SC-202 treatment at the concentrations indicated. b-Tubulin or total ERK1/2 served as loading controls for Western blots.
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but also reduced the ratio of Gli3 full-length activator (Gli3A)
to Gli3 repressor (Gli3R), suggesting that acetylation may also
contribute to efficient GLI repressor formation in addition to
its effect on DNA binding of GLI transcription factors
(Supporting Information, Figs. 6a and 6b).
Having shown a pronounced inhibitory effect of 4SC-202
on HH/GLI signaling and proliferation downstream of SMO,
we next investigated whether 4SC-202 treatment can repress
the in vivo growth of HH/GLI dependent BCC cells in a
preclinical in vivo model. To this end, we subcutaneously
injected into immunodeficient NOD-scid IL2Rgammanull
(NSG) mice ptch1/p53 double-deficient murine BCC cells
expressing readily detectable levels of Hdac1/2/3 in a Hh/Gli
independent manner as assessed by vismodegib treatment
(Supporting Information, Fig. 7). When tumors reached an
average volume of 400 mm3, we randomized the mice into
two groups. The verum group received 80 mg/kg/day of 4SC-
202 in 2% methocel solution, the control group was treated
with solvent only. Notably, treatment of BCC bearing mice
with 4SC-202 significantly decelerated in vivo tumor growth
Figure 2. 4SC-202 inhibits HH/GLI signaling by targeting class I HDACs rather than LSD1. (a) Summary of inhibitors used for chemical per-
turbations and their molecular targets. (b) qPCR analysis of GLI1 mRNA expression in SAG-stimulated Daoy cells in response to increasing
concentrations of the LSD1 blocker OG-L002. (c) GLI1 mRNA expression analysis in SAG-induced or control-treated Daoy cells transfected
with control siRNA (siControl) or siRNA against LSD1 (siLSD1). (d, e) qPCR analysis of GLI1 (d) and HHIP (e) mRNA expression in SAG-
stimulated Daoy cells in response to the HDAC1/2/3 inhibitor entinostat. (f) GLI1 mRNA expression in Daoy cells treated with the FDA-
approved pan-HDAC inhibitor SAHA (vorinostat).
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Figure 3. 4SC-202 inhibits HH/GLI signaling in SMOi-resistant cancer cells. (a) Western blot analysis of GLI1 expression in cells with lentiviral
shRNA-mediated knockdown of SUFU (shSUFU) or control knockdown (shControl). Beta Actin served as loading control. (b) qPCR analysis of GLI1
mRNA expression in SUFU knockdown (shSUFU) and control cells (shControl) transduced with lentiviral nontargeting scrambled shRNA. (c and d)
qPCR analysis of GLI1 (c) and HHIP mRNA expression (d) as readout for HH/GLI signaling activity in SUFU-depleted SMOi-resistant cells showing
resistance to vismodegib but sensitivity to 4SC-202 treatment. (e) Western blot analysis of SUFU-depleted Daoy cells treated with vismodegib or
4SC-202 at the concentrations indicated. b-Tubulin served as loading control. Vismodegib was unable to reduce GLI1 protein levels, while 4SC-
202 treatment effectively abolished GLI1 protein expression. (f) Relative densitometric quantification of GLI1/b-Tubulin protein levels shown in (e).
(g) ChIP analysis of MYC-tagged GLI1 binding to the GLI target promoter PTCH in response to control or 4SC-202 treatment. Enrichment of GLI1
bound promoter DNA was measured by qPCR. IgG isotype antibody was used as control. (h) Murine BCC cells were subcutaneously injected into
dorsal flanks of 12 NSG mice. 4SC-202 was administered by oral gavage at 80 mg/kg/day. The tumor volume at day 0 (i.e., start of drug treatment
(arrow)) was set to 100%. (i) Western blot analysis of solvent (allografts #1–#4) and 4SC-202 treated (allografts #5–#8) BCC lysates probed for
proliferation-cell-nuclear-antigen (Pcna) and Ccnd1 expression. Erk1/2 expression served as loading control. (j) Analysis of in vitro cell proliferation
of murine BCC cells in response to 4SC-202 and entinostat treatment. ChIP: chromatin immunoprecipitation. **p<0.01, ***p<0.001.
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(Fig. 3h), and markedly repressed the expression of the pro-
liferation marker PCNA, which was paralleled by a moderate
reduction of the Hh/Gli target gene and cell cycle regulator
Cyclin d1 (Ccnd1)7 (Fig. 3i). To support a direct effect of
4SC-202 on the growth of murine BCC cells, we treated
ptch1/p53-deficient cells also in vitro and found reduced cel-
lular proliferation in response to 4SC-202 as well as entino-
stat (Fig. 3j).
Together with high level expression of HDAC1 and
HDAC2 in human BCC samples (Supporting Information,
Fig. 8), our findings therefore warrant further studies of 4SC-
202 and other class I HDACi as combination or second-line
drugs to tackle the problem of frequent SMOi-resistance
development observed in HH-driven cancers such as BCC.
Discussion
SMOi provide clear clinical benefit to BCC patients, though
rapid development of SMOi resistance and a priori insensitiv-
ity to SMO antagonists limit the therapeutic efficacy of SMO
targeting.11 The lack of efficacy can, at least in part, be attrib-
uted to the many possibilities of malignant cells to activate
GLI transcription factors in a noncanonical (SMO-indepen-
dent) manner. Examples for potent noncanonical and SMO-
independent GLI activator signals include TGFb, RAS,
MAPK/ERK, DYRKs, PI3K/AKT, EWS-FLI1 and others.5,23
In this study, we identify the potent and clinically suitable
class I HDACi, 4SC-202, as novel inhibitor of HH/GLI sig-
naling in human cancer cells. Importantly, 4SC-202 but not
the FDA-approved inhibitor vismodegib, efficiently abrogated
HH/GLI signaling in SUFU-depleted human medulloblas-
toma cells resistant to SMOi-therapy. The SMO-independent
mode of action of 4SC-202 may lead to benefits for patients,
who do not qualify for therapy with SMOi either due to
acquired or a priori SMOi resistance. Inhibition of GLI tran-
scription factors is also an attractive strategy as GLI tran-
scription factors frequently integrate with other oncogenic
signaling cascades, thereby contributing to cancer progression
and malignant traits of cancer and cancer stem cells.5
Mechanistically, our results are in agreement with a previous
study by Canettieri et al., who showed that acetylation of GLI
proteins negatively regulates their DNA-binding capacity.24 In
fact, we found that 4SC-202 treatment strongly reduced binding
of the GLI1 oncogene to the PTCH target promoter despite
inducing an active chromatin as evidenced by increased H3K27
acetylation levels. In addition, class I HDACs may also act at the
level of GLI processing, as we found that 4SC-202 treatment
increased the level of Gli3R in Ptch1-deficient mouse medullo-
blastoma cells. Whether this is due to increased Gli3 acetylation
remains to be addressed in follow-up studies.
Previous studies have also identified interactions between
different HDACs and HH/GLI signaling, though with par-
tially different results. Canettieri et al. demonstrated a posi-
tive feedforward loop involving upregulation of HDAC1
expression in response to HH/GLI,12 while Dhanyamraju
et al. describe a positive role of HDAC6 in the regulation of
the mammalian HH pathway.13 By contrast, inhibition of
HDAC6 has also been shown to restore primary ciliogenesis,
thereby compensating for reduced HH signaling in STK11/
LKB1-depleted cells.14 HDAC6 may therefore exert context-
dependent positive and negative functions in the regulation
of the HH/GLI pathway, which may also explain the failure
of the FDA-approved pan-HDACi SAHA/vorinostat to effi-
ciently inhibit HH/GLI signaling in medulloblastoma cells.
Intriguingly, analysis of the genetic landscape of SHH sub-
group medulloblastoma identified frequent somatic alterations
in genes encoding histone acetyl transferases.25 In light of these
findings, our data together with the previous studies by the Can-
ettieri group may provide a mechanistic basis for this observa-
tion and guide possible new therapeutic approaches.
The clinical relevance of our findings is further underlined
by a recent phase I clinical trial with 4SC-202, where 18 out of
24 patients with advanced hematologic malignancies went into
follow up treatment, one patient showed complete response
and remained on study medication for >28 months, while
another patient had a partial response over a period of 8 months
(Clinical trial: NCT01344707, poster J Clin Oncol 32:5 sec,
2014 (suppl; abstr 8559)). Although it is unclear whether the
promising clinical response to 4SC-202 treatment was due to
inhibition of GLI activity, the results of the present study
warrant further clinical evaluation of 4SC-202 as a treatment
for GLI-dependent cancers including BCC, medulloblastoma
and possibly other malignancies with high medical need.
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